MX2023002269A - Inhibidores de apol1 y metodos para usar los mismos. - Google Patents

Inhibidores de apol1 y metodos para usar los mismos.

Info

Publication number
MX2023002269A
MX2023002269A MX2023002269A MX2023002269A MX2023002269A MX 2023002269 A MX2023002269 A MX 2023002269A MX 2023002269 A MX2023002269 A MX 2023002269A MX 2023002269 A MX2023002269 A MX 2023002269A MX 2023002269 A MX2023002269 A MX 2023002269A
Authority
MX
Mexico
Prior art keywords
same
apol1
methods
tautomer
inhibitors
Prior art date
Application number
MX2023002269A
Other languages
English (en)
Inventor
John E Cochran
Brad D Maxwell
Jon H Come
Michael Aaron Brodney
Jingrong Cao
Leslie A Dakin
Suganthini S Nanthakumar
Timothy J Senter
Haoxuan Wang
Jun Myun Ahn
Samantha Angle
Elena Dolgikh
Hardwin O´Dowd
Jessica Howard Olsen
Akira Joseph Shimizu
Steven David Stone
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2023002269A publication Critical patent/MX2023002269A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona al menos una entidad elegida de los Compuestos de la Fórmula I, un tautómero del mismo, un derivado deuterado de ese compuesto o tautómero, y una sal farmacéuticamente aceptable de cualquiera de los anteriores, composiciones que comprenden los mismos, y métodos para usar los mismos, incluyendo los usos en el tratamiento de enfermedades mediadas por APOL1, incluyendo cáncer pancreático, glomeruloesclerosis segmentaria focal (FSGS), y/o enfermedad renal no diabética (NDKD). (ver Fórmula).
MX2023002269A 2020-08-26 2021-08-26 Inhibidores de apol1 y metodos para usar los mismos. MX2023002269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063070705P 2020-08-26 2020-08-26
PCT/US2021/047754 WO2022047031A1 (en) 2020-08-26 2021-08-26 Inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
MX2023002269A true MX2023002269A (es) 2023-05-16

Family

ID=77822053

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002269A MX2023002269A (es) 2020-08-26 2021-08-26 Inhibidores de apol1 y metodos para usar los mismos.

Country Status (20)

Country Link
US (1) US11866446B2 (es)
EP (1) EP4204423A1 (es)
JP (1) JP2023539194A (es)
KR (1) KR20230057386A (es)
CN (1) CN116547287A (es)
AR (1) AR123355A1 (es)
AU (1) AU2021333776A1 (es)
BR (1) BR112023003423A2 (es)
CA (1) CA3190609A1 (es)
CL (1) CL2023000536A1 (es)
CO (1) CO2023003026A2 (es)
CR (1) CR20230132A (es)
DO (1) DOP2023000042A (es)
EC (1) ECSP23020167A (es)
IL (1) IL300298A (es)
MX (1) MX2023002269A (es)
PE (1) PE20231106A1 (es)
TW (1) TW202227456A (es)
UY (1) UY39395A (es)
WO (1) WO2022047031A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453760B (zh) 2018-12-17 2024-05-24 弗特克斯药品有限公司 Apol1抑制剂及其使用方法
US12116343B2 (en) 2020-01-29 2024-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
JP2023515668A (ja) 2020-03-06 2023-04-13 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ－１依存性巣状分節性糸球体硬化症を治療する方法
IL300298A (en) 2020-08-26 2023-04-01 Vertex Pharma Apol1 inhibitors and methods of using the same
MX2024002229A (es) * 2021-08-26 2024-05-15 Vertex Pharma Formas solidas de inhibidores de apolipoproteina l1 (apol1) espirotriciclicos y metodos de uso de las mismas.
KR20240149461A (ko) 2022-01-18 2024-10-14 메이즈 테라퓨틱스, 인코퍼레이티드 Apol1 저해제 및 사용 방법
WO2023154344A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
AU3784997A (en) 1996-08-09 1998-03-06 Eisai Co. Ltd. Benzopiperidine derivatives
AU7514700A (en) 1999-09-07 2001-04-10 Syngenta Participations Ag Cyanopiperidines
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
CA2424222A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
ES2414604T3 (es) 2004-03-03 2013-07-22 Eli Lilly And Company Moduladores del receptor nuclear de hormonas esteroides de derivados bicíclicos sustituidos con indol
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
CA2666406A1 (en) 2006-10-16 2008-04-24 Gruenenthal Gmbh Substituted sulfonamide derivatives for use as bradykinin 1 receptor modulators
WO2008077810A2 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
CA2676984C (en) 2007-02-01 2015-03-17 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
US8436038B2 (en) 2007-08-17 2013-05-07 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
MX2011012712A (es) 2009-05-29 2012-01-30 Raqualia Pharma Inc Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
UA107943C2 (en) 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
US20120214784A1 (en) 2009-11-16 2012-08-23 Eli Lilly And Company Spiropiperidine compounds as orl-1 receptor antagonists
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
WO2014085154A1 (en) 2012-11-27 2014-06-05 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
EP3049405A4 (en) 2013-09-26 2017-03-08 Pharmakea Inc. Autotaxin inhibitor compounds
EP3186225A4 (en) 2014-08-27 2018-02-28 The Governing Council of the University of Toronto Cannabinoid type 1 receptor modulators
ES2751623T3 (es) 2014-10-08 2020-04-01 Inst Nat Sante Rech Med Nuevos compuestos de aminopiridina útiles como inhibidores de la prenilación de proteínas
CA2967097A1 (en) 2014-11-21 2016-05-26 Laboratorios Del Dr. Esteve, S.A. Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain
WO2017033093A1 (en) 2015-08-27 2017-03-02 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators
CN108884096B (zh) 2016-02-08 2022-03-22 豪夫迈·罗氏有限公司 作为ddr1抑制剂的螺二氢吲哚酮
WO2019213148A1 (en) 2018-04-30 2019-11-07 Vasculonics Llc Compounds for modulating ddah and adma levels, as well as methods of using thereof to treat disease
CN113453760B (zh) 2018-12-17 2024-05-24 弗特克斯药品有限公司 Apol1抑制剂及其使用方法
WO2020186220A1 (en) 2019-03-13 2020-09-17 Immunophage Biomedical Co., Ltd. Compounds as inhibitors of macrophage migration inhibitory factor
JP2023508930A (ja) 2019-12-19 2023-03-06 カスマ セラピューティクス， インコーポレイテッド Ｔｒｐｍｌモジュレーター
US12116343B2 (en) 2020-01-29 2024-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
US20210246121A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
JP2023515668A (ja) 2020-03-06 2023-04-13 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ－１依存性巣状分節性糸球体硬化症を治療する方法
AU2021259580A1 (en) 2020-04-22 2022-11-24 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
AU2021268129A1 (en) 2020-05-07 2022-12-08 Rambam Med-Tech Ltd. Composition for use in the treatment of ApoL1-associated disease
WO2021252859A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CA3185144A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
JP2023530276A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１阻害剤の固体形態及びその使用
IL300298A (en) 2020-08-26 2023-04-01 Vertex Pharma Apol1 inhibitors and methods of using the same
MX2024002229A (es) 2021-08-26 2024-05-15 Vertex Pharma Formas solidas de inhibidores de apolipoproteina l1 (apol1) espirotriciclicos y metodos de uso de las mismas.

Also Published As

Publication number Publication date
CR20230132A (es) 2023-06-27
US20220106327A1 (en) 2022-04-07
CA3190609A1 (en) 2022-03-03
ECSP23020167A (es) 2023-12-29
WO2022047031A1 (en) 2022-03-03
CL2023000536A1 (es) 2023-09-08
IL300298A (en) 2023-04-01
BR112023003423A2 (pt) 2023-03-21
CO2023003026A2 (es) 2023-03-17
UY39395A (es) 2022-03-31
EP4204423A1 (en) 2023-07-05
PE20231106A1 (es) 2023-07-19
DOP2023000042A (es) 2023-07-09
KR20230057386A (ko) 2023-04-28
AU2021333776A1 (en) 2023-03-16
CN116547287A (zh) 2023-08-04
TW202227456A (zh) 2022-07-16
AR123355A1 (es) 2022-11-23
US11866446B2 (en) 2024-01-09
JP2023539194A (ja) 2023-09-13

Similar Documents

Publication Publication Date Title
MX2023002269A (es) Inhibidores de apol1 y metodos para usar los mismos.
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
EP4356973A3 (en) 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
MX2021007152A (es) Inhibidores de apol1 y sus metodos de uso.
CR20240261A (es) Derivados de 4-fenil-2-(1h-1,2,3-triazol-4-il)piperidin-4-ol como inhibidores de apol1 y métodos para usar los mismos
CR20200376A (es) Inhibidores de cd73
LTPA2016016I1 (lt) Azetinidai kaip mek inhibitoriai, skirti proliferacinių ligų gydymui
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EP3693369A3 (en) Bromodomain inhibitors
MX2023012726A (es) Compuestos heterociclicos y metodos de uso.
MX2024001893A (es) Compuestos heterociclicos y metodos de uso.
NO20083207L (no) Inhibitorer av IAP
EA200700902A1 (ru) 3-ариламинопиридиновые производные
UA84175C2 (ru) Гетероциклические ингибиторы мэк и их применение
MX2024001894A (es) Compuestos heterociclicos y metodos de uso.
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
MX2019009653A (es) Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos.
CO2024012060A2 (es) Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2022010748A (es) Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
MX2021012105A (es) Compuestos de pirrol.
SA521420951B1 (ar) مركبات ترايازول تعمل كمثبطات للجليكولات أوكسيداز
EA202192760A1 (ru) Трициклические соединения
PH12021550323A1 (en) Dendrimer formulations